Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis

• Hirokazu Honda ,

  * E-mail: hondah@med.showa-u.ac.jp

  Affiliation Division of Nephrology, Department of Medicine, Showa University Koto Toyusu Hospital, Tokyo, Japan

  ⨯
• Yasuna Kobayashi,

  Affiliation Division of Clinical Pharmacy, Department of Pharmacotherapeutics, Showa University, School of Pharmacy, Tokyo, Japan

  ⨯
• Shoko Onuma,

  Affiliation Division of Nephrology, Department of Medicine, Showa University, School of Medicine, Tokyo, Japan

  ⨯
• Keigo Shibagaki,

  Affiliation Shibagaki Dialysis Clinic Jiyugaoka, Tokyo, Japan

  ⨯
• Toshitaka Yuza,

  Affiliation Shibagaki Dialysis Clinic Jiyugaoka, Tokyo, Japan

  ⨯
• Keiichi Hirao,

  Affiliation Shibagaki Dialysis Clinic Togoshi, Tokyo, Japan

  ⨯
• Toshinori Yamamoto,

  Affiliation Division of Clinical Pharmacy, Department of Pharmacotherapeutics, Showa University, School of Pharmacy, Tokyo, Japan

  ⨯
• Naohisa Tomosugi,

  Affiliation Aging Research Unit, Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Kanazawa, Japan

  ⨯
• Takanori Shibata

  Affiliation Division of Nephrology, Department of Medicine, Showa University, School of Medicine, Tokyo, Japan

  ⨯